BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division

Reuters11-17
BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division

** ASX-listed shares of inflammatory disease drug-maker Mesoblast MSB.AX rise as much 3.6% to A$2.3, snapping two sessions of consecutive losses

** Co appoints James O'Brien as its U.S.-based CFO

** Says Jim's recent CFO roles included NASDAQ-listed biopharmaceutical company Cognition Therapeutics Inc CGTX.O, overseeing successful initial public offering, among others

** Stock is fourth-biggest percentage gainer in the benchmark S&P/ASX 200 index .AXJO

** Stock up 2.7% at A$2.28, as at 0104 GMT

** Stock down 26.5% this year, including the day's move

(Reporting by Roushni Nair in Bengaluru)

((Roushni.nair@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment